AAPL302.22+7.84 (+2.66%) ▲|ABBV254.12+3.06 (+1.22%) ▲|ABT92.26+0.08 (+0.09%) ▲|ACN134.93+3.80 (+2.90%) ▲|ADBE218.27+7.29 (+3.45%) ▲|AMAT643.04-7.87 (-1.21%) ▼|AMD536.49-4.39 (-0.81%) ▼|AMGN368.12+6.79 (+1.88%) ▲|AMT168.16+2.08 (+1.25%) ▲|AMZN243.25+1.55 (+0.64%) ▲|AVGO371.12+1.78 (+0.48%) ▲|AXP347.44+0.39 (+0.11%) ▲|BA226.81+8.23 (+3.77%) ▲|BAC58.13-0.23 (-0.39%) ▼|BKNG183.59+0.95 (+0.52%) ▲|BLK993.05+12.67 (+1.29%) ▲|BMY57.29+1.48 (+2.64%) ▲|BNY146.75+0.73 (+0.50%) ▲|BRK-B502.35+2.61 (+0.52%) ▲|C140.79+0.66 (+0.47%) ▲|CAT996.12+4.71 (+0.48%) ▲|CL93.74+0.98 (+1.06%) ▲|CMCSA23.66-0.08 (-0.32%) ▼|COF205.69+0.87 (+0.42%) ▲|COP104.22+1.00 (+0.97%) ▲|COST928.04+3.37 (+0.36%) ▲|CRM164.80+1.57 (+0.96%) ▲|CSCO115.66-1.36 (-1.16%) ▼|CVS104.58-0.23 (-0.22%) ▼|CVX168.85+3.16 (+1.91%) ▲|DE637.07+9.44 (+1.50%) ▲|DHR195.65+1.93 (+1.00%) ▲|DIS95.91+0.20 (+0.21%) ▲|DUK126.61+0.84 (+0.67%) ▲|EMR141.47+1.95 (+1.40%) ▲|FDX314.92+1.03 (+0.33%) ▲|GD368.81+6.02 (+1.66%) ▲|GE380.72+5.79 (+1.54%) ▲|GEV1,129.86-4.87 (-0.43%) ▼|GILD127.56+1.59 (+1.26%) ▲|GM75.95+0.41 (+0.54%) ▲|GOOG360.11+2.22 (+0.62%) ▲|GOOGL363.47+2.26 (+0.63%) ▲|GS1,036.49+16.78 (+1.65%) ▲|HD349.32-1.58 (-0.45%) ▼|HON223.68+1.93 (+0.87%) ▲|IBM289.12+2.85 (+1.00%) ▲|INTC129.09+2.07 (+1.63%) ▲|INTU271.60+4.52 (+1.69%) ▲|ISRG411.44+9.06 (+2.25%) ▲|JNJ256.99+3.04 (+1.20%) ▲|JPM332.92-1.16 (-0.35%) ▼|KO81.63+0.32 (+0.39%) ▲|LIN540.54+6.99 (+1.31%) ▲|LLY1,208.63+16.72 (+1.40%) ▲|LMT538.92+17.22 (+3.30%) ▲|LOW222.13+0.26 (+0.12%) ▲|LRCX384.51-6.75 (-1.73%) ▼|MA527.43+4.93 (+0.94%) ▲|MCD272.63+3.16 (+1.17%) ▲|MDLZ60.15+0.80 (+1.35%) ▲|MDT80.04+0.83 (+1.05%) ▲|META592.61-20.30 (-3.31%) ▼|MMM160.82+0.77 (+0.48%) ▲|MO72.28+0.72 (+1.01%) ▲|MRK127.22+1.81 (+1.44%) ▲|MS214.77+2.92 (+1.38%) ▲|MSFT385.47+1.19 (+0.31%) ▲|MU1,056.49+24.21 (+2.35%) ▲|NEE86.90+0.51 (+0.59%) ▲|NFLX75.51+1.32 (+1.78%) ▲|NKE44.70+1.56 (+3.60%) ▲|NOW105.74-0.03 (-0.03%) ▼|NVDA197.98+0.40 (+0.20%) ▲|ORCL145.80+3.07 (+2.15%) ▲|PEP142.82+1.66 (+1.18%) ▲|PFE24.33+0.44 (+1.82%) ▲|PG148.47+1.03 (+0.70%) ▲|PLTR130.68+4.95 (+3.94%) ▲|PM180.90+3.22 (+1.81%) ▲|QCOM182.72+0.80 (+0.44%) ▲|RTX196.83+5.06 (+2.64%) ▲|SBUX103.76+0.37 (+0.35%) ▲|SCHW96.46+0.69 (+0.72%) ▲|SO95.68+0.55 (+0.57%) ▲|SPG223.60+0.51 (+0.23%) ▲|T20.89+0.40 (+1.93%) ▲|TMO520.70+7.20 (+1.40%) ▲|TMUS176.00+2.94 (+1.70%) ▲|TSLA412.61-12.69 (-2.98%) ▼|TXN303.63+5.22 (+1.75%) ▲|UBER73.32+0.65 (+0.89%) ▲|UNH429.13+2.70 (+0.63%) ▲|UNP281.81+4.10 (+1.47%) ▲|UPS110.54+1.04 (+0.95%) ▲|USB61.99+0.03 (+0.05%) ▲|V354.78+3.68 (+1.05%) ▲|VZ42.81+0.82 (+1.95%) ▲|WFC85.72-0.23 (-0.26%) ▼|WMT110.79+1.97 (+1.81%) ▲|XOM138.51+2.23 (+1.63%) ▲|AAPL302.22+7.84 (+2.66%) ▲|ABBV254.12+3.06 (+1.22%) ▲|ABT92.26+0.08 (+0.09%) ▲|ACN134.93+3.80 (+2.90%) ▲|ADBE218.27+7.29 (+3.45%) ▲|AMAT643.04-7.87 (-1.21%) ▼|AMD536.49-4.39 (-0.81%) ▼|AMGN368.12+6.79 (+1.88%) ▲|AMT168.16+2.08 (+1.25%) ▲|AMZN243.25+1.55 (+0.64%) ▲|AVGO371.12+1.78 (+0.48%) ▲|AXP347.44+0.39 (+0.11%) ▲|BA226.81+8.23 (+3.77%) ▲|BAC58.13-0.23 (-0.39%) ▼|BKNG183.59+0.95 (+0.52%) ▲|BLK993.05+12.67 (+1.29%) ▲|BMY57.29+1.48 (+2.64%) ▲|BNY146.75+0.73 (+0.50%) ▲|BRK-B502.35+2.61 (+0.52%) ▲|C140.79+0.66 (+0.47%) ▲|CAT996.12+4.71 (+0.48%) ▲|CL93.74+0.98 (+1.06%) ▲|CMCSA23.66-0.08 (-0.32%) ▼|COF205.69+0.87 (+0.42%) ▲|COP104.22+1.00 (+0.97%) ▲|COST928.04+3.37 (+0.36%) ▲|CRM164.80+1.57 (+0.96%) ▲|CSCO115.66-1.36 (-1.16%) ▼|CVS104.58-0.23 (-0.22%) ▼|CVX168.85+3.16 (+1.91%) ▲|DE637.07+9.44 (+1.50%) ▲|DHR195.65+1.93 (+1.00%) ▲|DIS95.91+0.20 (+0.21%) ▲|DUK126.61+0.84 (+0.67%) ▲|EMR141.47+1.95 (+1.40%) ▲|FDX314.92+1.03 (+0.33%) ▲|GD368.81+6.02 (+1.66%) ▲|GE380.72+5.79 (+1.54%) ▲|GEV1,129.86-4.87 (-0.43%) ▼|GILD127.56+1.59 (+1.26%) ▲|GM75.95+0.41 (+0.54%) ▲|GOOG360.11+2.22 (+0.62%) ▲|GOOGL363.47+2.26 (+0.63%) ▲|GS1,036.49+16.78 (+1.65%) ▲|HD349.32-1.58 (-0.45%) ▼|HON223.68+1.93 (+0.87%) ▲|IBM289.12+2.85 (+1.00%) ▲|INTC129.09+2.07 (+1.63%) ▲|INTU271.60+4.52 (+1.69%) ▲|ISRG411.44+9.06 (+2.25%) ▲|JNJ256.99+3.04 (+1.20%) ▲|JPM332.92-1.16 (-0.35%) ▼|KO81.63+0.32 (+0.39%) ▲|LIN540.54+6.99 (+1.31%) ▲|LLY1,208.63+16.72 (+1.40%) ▲|LMT538.92+17.22 (+3.30%) ▲|LOW222.13+0.26 (+0.12%) ▲|LRCX384.51-6.75 (-1.73%) ▼|MA527.43+4.93 (+0.94%) ▲|MCD272.63+3.16 (+1.17%) ▲|MDLZ60.15+0.80 (+1.35%) ▲|MDT80.04+0.83 (+1.05%) ▲|META592.61-20.30 (-3.31%) ▼|MMM160.82+0.77 (+0.48%) ▲|MO72.28+0.72 (+1.01%) ▲|MRK127.22+1.81 (+1.44%) ▲|MS214.77+2.92 (+1.38%) ▲|MSFT385.47+1.19 (+0.31%) ▲|MU1,056.49+24.21 (+2.35%) ▲|NEE86.90+0.51 (+0.59%) ▲|NFLX75.51+1.32 (+1.78%) ▲|NKE44.70+1.56 (+3.60%) ▲|NOW105.74-0.03 (-0.03%) ▼|NVDA197.98+0.40 (+0.20%) ▲|ORCL145.80+3.07 (+2.15%) ▲|PEP142.82+1.66 (+1.18%) ▲|PFE24.33+0.44 (+1.82%) ▲|PG148.47+1.03 (+0.70%) ▲|PLTR130.68+4.95 (+3.94%) ▲|PM180.90+3.22 (+1.81%) ▲|QCOM182.72+0.80 (+0.44%) ▲|RTX196.83+5.06 (+2.64%) ▲|SBUX103.76+0.37 (+0.35%) ▲|SCHW96.46+0.69 (+0.72%) ▲|SO95.68+0.55 (+0.57%) ▲|SPG223.60+0.51 (+0.23%) ▲|T20.89+0.40 (+1.93%) ▲|TMO520.70+7.20 (+1.40%) ▲|TMUS176.00+2.94 (+1.70%) ▲|TSLA412.61-12.69 (-2.98%) ▼|TXN303.63+5.22 (+1.75%) ▲|UBER73.32+0.65 (+0.89%) ▲|UNH429.13+2.70 (+0.63%) ▲|UNP281.81+4.10 (+1.47%) ▲|UPS110.54+1.04 (+0.95%) ▲|USB61.99+0.03 (+0.05%) ▲|V354.78+3.68 (+1.05%) ▲|VZ42.81+0.82 (+1.95%) ▲|WFC85.72-0.23 (-0.26%) ▼|WMT110.79+1.97 (+1.81%) ▲|XOM138.51+2.23 (+1.63%) ▲|
34.6 C
New York
Thursday, July 2, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC

66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days89% of healthcare professionals...

Kelun-Biotech’s Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that the Company has received a clinical trial notice...

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the...

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Shelby Dermatology d/b/a Dermatologists of Birmingham Clients Whose Data May Have Been...

NEWTOWN, Pa., June 11, 2025 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Shelby...

MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline

MediPharm reminds shareholders to vote for proven strategy and team in advance of deadline, July 13, 2025 at 3:00pm EDT.

MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting

Ontario Superior Court of Justice fully dismisses application by dissident shareholder Apollo against MediPharm Labs.

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Topeka’s KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer

BURR RIDGE, Ill., June 11, 2025 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of...

SATISFACTION WITH CARE EXPERIENCES MAKES A SIGNIFICANT DIFFERENCE FOR CANCER SURVIVORS, AREA ONCOLOGIST SAYS

SOMERSET, N.J., June 11, 2025 /PRNewswire/ -- In honor of National Cancer Survivor Month, ProCure Proton Therapy Center highlights a vital element in the care journey:...

Norton Children’s announces new pediatric care campus, second dedicated pediatric hospital

New campus will expand specialty care and research for children from across the region 
New campus will expand specialty care and research for children from across the region

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers